Cargando…

Recent advances of highly selective CDK4/6 inhibitors in breast cancer

Uncontrolled cell division is the hallmark of cancers. Full understanding of cell cycle regulation would contribute to promising cancer therapies. In particular, cyclin-dependent kinases 4/6 (CDK4/6), which are pivotal drivers of cell proliferation by combination with cyclin D, draw more and more at...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Hanxiao, Yu, Shengnan, Liu, Qian, Yuan, Xun, Mani, Sridhar, Pestell, Richard G., Wu, Kongming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5404666/ https://www.ncbi.nlm.nih.gov/pubmed/28438180 http://dx.doi.org/10.1186/s13045-017-0467-2

Ejemplares similares

Recent advances of bispecific antibodies in solid tumors
por: Yu, Shengnan, et al.
Publicado: (2017)

DACH1 suppresses breast cancer as a negative regulator of CD44
por: Xu, Hanxiao, et al.
Publicado: (2017)

The role of CD44 in epithelial–mesenchymal transition and cancer development
por: Xu, Hanxiao, et al.
Publicado: (2015)

Endogenous Dach1 in cancer
por: Wu, Kongming, et al.
Publicado: (2015)

CDK4/6 inhibitors in advanced breast cancer, what is beyond?
por: Mohammed, Amrallah A., et al.
Publicado: (2019)

Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
por: Qin, Shuang, et al.
Publicado: (2019)

Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
por: Al-Qasem, Abeer J., et al.
Publicado: (2022)

Current Therapeutic Progress of CDK4/6 Inhibitors in Breast Cancer
por: Wu, Yanmei, et al.
Publicado: (2020)

Gut microbiome modulates efficacy of immune checkpoint inhibitors
por: Yi, Ming, et al.
Publicado: (2018)

Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer
por: Lu, Janice
Publicado: (2015)

The Renaissance of CDK Inhibitors in Breast Cancer Therapy: An Update on Clinical Trials and Therapy Resistance
por: Abdelmalak, Mary, et al.
Publicado: (2022)

Biological functions of CDK5 and potential CDK5 targeted clinical treatments
por: Shupp, Alison, et al.
Publicado: (2017)

The role of CDK4/6 inhibitors in early breast cancer
por: Gil-Gil, Miguel, et al.
Publicado: (2021)

Recent advances with cyclin-dependent kinase inhibitors: therapeutic agents for breast cancer and their role in immuno-oncology
por: Di Sante, Gabriele, et al.
Publicado: (2019)

Inducible deletion of CDK4 and CDK6 – deciphering CDK4/6 inhibitor effects in the hematopoietic system
por: Maurer, Barbara, et al.
Publicado: (2020)

CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors
por: Schettini, Francesco, et al.
Publicado: (2018)

Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2− advanced breast cancer
por: Corona, Silvia Paola, et al.
Publicado: (2018)

Safety and Feasibility of Radiation Therapy Combined with CDK 4/6 Inhibitors in the Management of Advanced Breast Cancer
por: Kubeczko, Marcin, et al.
Publicado: (2023)

Medication-Related Osteonecrosis of the Jaws and CDK4/6 Inhibitors: A Recent Association
por: Marcianò, Antonia, et al.
Publicado: (2020)

Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors
por: Piezzo, Michela, et al.
Publicado: (2020)

Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer
por: Li, Zhen, et al.
Publicado: (2020)

Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer
por: George, Mridula A., et al.
Publicado: (2021)

Clinical CDK4/6 inhibitors induce selective and immediate dissociation of p21 from cyclin D-CDK4 to inhibit CDK2
por: Pack, Lindsey R., et al.
Publicado: (2021)

Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
por: Yang, C, et al.
Publicado: (2017)

Analysis of the selection of CDK4/6 inhibitors based on experience using palbociclib
por: Kikuchi, Mariko, et al.
Publicado: (2019)

Expression of Notch1 Correlates with Breast Cancer Progression and Prognosis
por: Yuan, Xun, et al.
Publicado: (2015)

The CDK4/6 inhibitor in HR-positive advanced breast cancer: A systematic review and meta-analysis
por: Ding, Wu, et al.
Publicado: (2018)

Ribociclib, a CDK 4/6 inhibitor, plus endocrine therapy in Asian women with advanced breast cancer
por: Yap, Yoon‐Sim, et al.
Publicado: (2020)

CDK 4/6 inhibitors for the treatment of meningioma
por: Young, Jacob S., et al.
Publicado: (2022)

CDK4/6 inhibition in luminal breast cancer
por: Gampenrieder, Simon Peter, et al.
Publicado: (2016)

Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer
por: Scheidemann, Erin R., et al.
Publicado: (2021)

Potential Prospect of CDK4/6 Inhibitors in Triple-Negative Breast Cancer
por: Hu, Ye, et al.
Publicado: (2021)

Is there a role for CDK 4/6 inhibitors in breast cancer brain metastases?
por: Schlam, Ilana, et al.
Publicado: (2021)

Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer()
por: Loibl, Sibylle, et al.
Publicado: (2021)

The Evolving Pathways of the Efficacy of and Resistance to CDK4/6 Inhibitors in Breast Cancer
por: Gomes, Inês, et al.
Publicado: (2023)

Adverse kidney outcomes of CDK 4/6 inhibitors for metastatic breast cancer
por: Hanna, Paul E., et al.
Publicado: (2023)

CDK4/6 inhibitor resistance: A bibliometric analysis
por: Pang, Jiayuecheng, et al.
Publicado: (2022)

Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments
por: Xiao, Lanshu, et al.
Publicado: (2023)

Overcoming Endocrine Resistance in Hormone-Receptor Positive Advanced Breast Cancer-The Emerging Role of CDK4/6 Inhibitors
por: O’Sullivan, Ciara C
Publicado: (2015)

Real-world outcomes from use of CDK4/6 inhibitors in the management of advanced/metastatic breast cancer in Asia
por: Low, Jia Li, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_76mddiocijt4vobivsqc7pbqtc